223 related articles for article (PubMed ID: 11817657)
1. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.
Wilson EM; Spinale FG
Ann Med; 2001 Dec; 33(9):623-34. PubMed ID: 11817657
[TBL] [Abstract][Full Text] [Related]
2. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
Spinale FG; Coker ML; Bond BR; Zellner JL
Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
Spinale FG
Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
[TBL] [Abstract][Full Text] [Related]
6. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007.
Graham HK; Horn M; Trafford AW
Acta Physiol (Oxf); 2008 Sep; 194(1):3-21. PubMed ID: 18577182
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
[TBL] [Abstract][Full Text] [Related]
8. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors.
Kassiri Z; Khokha R
Thromb Haemost; 2005 Feb; 93(2):212-9. PubMed ID: 15711735
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices.
Li YY; Feng Y; McTiernan CF; Pei W; Moravec CS; Wang P; Rosenblum W; Kormos RL; Feldman AM
Circulation; 2001 Sep; 104(10):1147-52. PubMed ID: 11535571
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.
Lindsey ML; Iyer RP; Jung M; DeLeon-Pennell KY; Ma Y
J Mol Cell Cardiol; 2016 Feb; 91():134-40. PubMed ID: 26721597
[TBL] [Abstract][Full Text] [Related]
11. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
Goetzenich A; Hatam N; Zernecke A; Weber C; Czarnotta T; Autschbach R; Christiansen S
J Heart Lung Transplant; 2009 Oct; 28(10):1087-93. PubMed ID: 19782292
[TBL] [Abstract][Full Text] [Related]
12. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
[TBL] [Abstract][Full Text] [Related]
13. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
Vanhoutte D; Schellings M; Pinto Y; Heymans S
Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
[TBL] [Abstract][Full Text] [Related]
14. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
[TBL] [Abstract][Full Text] [Related]
15. Matrix metallopropteinases in heart failure.
Tousoulis D; Kampoli AM; Papageorgiou N; Antoniades C; Siasos G; Latsios G; Tsiamis E; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1181-91. PubMed ID: 22519448
[TBL] [Abstract][Full Text] [Related]
16. MMP induction and inhibition in myocardial infarction.
Lindsey ML
Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
18. Matrix modulation and heart failure: new concepts question old beliefs.
Deschamps AM; Spinale FG
Curr Opin Cardiol; 2005 May; 20(3):211-6. PubMed ID: 15861009
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases in cardiovascular disease.
Liu P; Sun M; Sader S
Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):25B-30B. PubMed ID: 16498509
[TBL] [Abstract][Full Text] [Related]
20. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Li YY; McTiernan CF; Feldman AM
Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
